Haohai Biotechnology (06826) announced interim results. Net profit of about 113 million yuan decreased by 46.64% year on year

According to the Zhitong Finance App, Haohai Biotechnology (06826) announced its 2026 interim results, with operating income of about 1,166 billion yuan, a year-on-year decrease of about 9.81%; net profit attributable to shareholders of listed companies was about 113 million yuan, a year-on-year decrease of 46.64%; profit per share was 0.49 yuan, with an interim dividend of 0.25 yuan per share (tax included).

According to the announcement, the decrease in net profit was mainly due to a decrease in gross profit due to a decline in sales revenue, especially revenue from hyaluronic acid products. Combined with additional depreciation and amortization expenses of more than 21 million yuan due to the transformation of the medical device workshop and comprehensive supporting facilities of the Shanghai Haohai Biotech International Pharmaceutical R&D and industrialization project in February 2026 from ongoing construction projects.